---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-014829"
form_type: "8-K"
ticker: null
cik: "0001614067"
company_name: "Aridis Pharmaceuticals, Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:03:11.700586+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aridis Pharmaceuticals enters $9.3M note restructuring with Streeterville Capital, $2.5M new funding

## Summary
- Secured note principal up to $9.29M; $1M direct draw at closing, $1.5M escrowed for future draws.
- Interest at 8% per annum; maturity April 26, 2024; amortization of 16.67% monthly starting October 26, 2023.
- Covenants include maintaining Nasdaq listing, filing SEC reports, and no restricted issuances without Investor consent.
- Prepayment at 110% of outstanding balance; proceeds from JV sale or equity offering trigger mandatory prepayment.
- Prior note #2 ($5.25M original principal) cancelled; outstanding balance affirmed at $2.67M.

## SEC filing metadata
- accession: 0001493152-23-014829
- form_type: 8-K
- cik: 0001614067
- company_name: Aridis Pharmaceuticals, Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1614067/000149315223014829/0001493152-23-014829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1614067/000149315223014829/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-014829
- JSON: https://secwatch.observer/filing/0001493152-23-014829.json
- Plain text: https://secwatch.observer/filing/0001493152-23-014829.txt

## Key facts
- Debt Financings
  Aridis Pharmaceuticals, Inc. incurred loan of up to $9,286,770.80 with Streeterville Capital, LLC at 8% per annum maturing April 26, 2024.
  - Instrument: loan
  - Principal: up to $9,286,770.80
  - Counterparty: Streeterville Capital, LLC
  - Rate: 8% per annum
  - Maturity: April 26, 2024
  - Event: incurrence
  source text: Pursuant to the Agreement, the Investor agreed to invest an additional investment amount of up to $2,500,000, $1,000,000 of which will delivered to the Company at closing and the remaining $1,500,000 of which will be placed into escrow under a secured line of credit facility with the total original principal amount of the secured promissory note being up to $9,286,770.80 (the “Secured Note”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1614067/000149315223014829/0001493152-23-014829-index.htm
- Material Agreements
  Aridis Pharmaceuticals, Inc. entered into Note Purchase and Loan Restructuring Agreement with Streeterville Capital, LLC valued at up to $2,500,000 additional investment, total principal up to $9,286,770.80 (effective 2023-04-26).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Streeterville Capital, LLC
  - Value: up to $2,500,000 additional investment, total principal up to $9,286,770.80
  - Effective: 2023-04-26
  source text: On April 26, 2023, Aridis Pharmaceuticals, Inc. (the “Company”) entered into a Note Purchase and Loan Restructuring Agreement (the “Agreement”) with Streeterville Capital, LLC (the “Investor”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1614067/000149315223014829/0001493152-23-014829-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.